Kurs
+8,15%
Kurs
+8,15%
Open
36,80
High
39,80
Low
36,00
Close
39,80
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,61 MNOK
Likviditet
0,61 MNOK
Rel. mcap
0,10%
Antal aktier
15 990
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | N/A | Årsstämma |
| 2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2024-04-29 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2021-05-04 | - | Årsstämma |
| 2021-04-16 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-07-13 | - | Extra Bolagsstämma 2018 |
| 2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-06-06 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-04-29 14:20:12
Moss, 29 April 2024
The board of directors today appointed Mr. Njaal Kind as acting CEO of Gentian
Diagnostics ASA. Mr. Kind joined Gentian in January 2018 as CFO. More recently
he has been promoted to CFO/COO. During these years at Gentian, Mr. Kind has
significantly contributed to the outstanding financial performance of the
company. As acting CEO, Mr. Kind will also continue to serve as CFO and COO.
The company's general meeting has resolved to elect Ms. Hilja Ibert as
chairperson of the board of directors. Ms. Ibert has therefore resigned as CEO
effective today.
"It has been a pleasure to serve Gentian Diagnostics as CEO since July 2018. I
am impressed what the Gentian team has achieved during that period, in which
sales has resulted in a compounded annual growth rate of 30%. With my
transition to a board position, I am still committed to securing further
profitable growth and development of the company. Gentian is now in safe hands
with Njaal Kind as acting CEO. He is known and trusted by our stakeholders, and
I am confident that he will solve this mission in an excellent manner."
IR contact:
Njaal Kind, CEO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act